Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy (Q38408897)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 2015

Language	Label	Description	Also known as
English	Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy	scientific article published on March 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

1 reference

Europe PubMed Central

Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy (English)

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

author name string

Pilar López-Serrano

1

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Elsa de la Fuente Briongos

2

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Elisa Carrera Alonso

3

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Jose Lázaro Pérez-Calle

4

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Conrado Fernández Rodríguez

5

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

publication date

1 March 2015

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

World Journal of Hepatology

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

7

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

3

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

539-547

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Immunosuppression and HBV reactivation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Oral locally active steroids in inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Current trends in management of hepatitis B virus reactivation in the biologic therapy era

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Management of occult hepatitis B virus infection: an update for the clinician.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Chronic hepatitis B: update 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Budesonide for induction of remission in Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Management of hepatitis B: summary of a clinical research workshop

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Immunizations for high-risk populations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Budesonide in inflammatory bowel disease: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

6 September 2017

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

14 September 2017

Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area: a retrospective multicenter survey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

23 June 2018

The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

23 June 2018

Prevalence of hepatitis-B viral markers in patients with inflammatory bowel disease in a hepatitis-B-endemic area: inadequate protective antibody levels in young patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

23 June 2018

Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

23 June 2018

The effect of immune therapy on surgical site infection following Crohn's Disease resection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

23 June 2018

Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

23 June 2018

The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

23 June 2018

Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

23 June 2018

Immunization update: the latest ACIP recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Hepatitis B virus reactivation after ustekinumab treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Consensus document of the Spanish Association for the Study of the Liver on the treatment of hepatitis B infection (2012)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Reactivation of Hepatitis B Virus After Steroid Treatment in Rheumatic Diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Liver dysfunction in patients with IBD under immunosuppressive treatment: do we need to fear?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Entecavir for hepatitis B virus flare treatment in patients with Crohn's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Hepatitis B and C virus infection in Crohn's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Antibody to hepatitis B e positive hepatitis induced by withdrawal of steroid therapy for polymyositis: response to interferon-alpha and cyclosporin A.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

A population based survey of hepatitis B virus infection in a southern Italian town

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381176

31 August 2018

Alcohol, psoriasis, liver disease, and anti-psoriasis drugs

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.539

21 January 2018

Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.539

21 January 2018

Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France

1 reference

https://pubmed.ncbi.nlm.nih.gov/25848477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade®) en la enfermedad inflamatoria intestinal

1 reference

https://pubmed.ncbi.nlm.nih.gov/25848477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of hepatitis B reactivation following Rituximab therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25848477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Psoriasis associated with hepatitis C but not with hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/25848477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25848477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohnʼs disease patient

1 reference

https://pubmed.ncbi.nlm.nih.gov/25848477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of hepatitis B with antirheumatic drugs: a case-control study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25848477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update on adult immunization. Recommendations of the Immunization Practices Advisory Committee (ACIP)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25848477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25848477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/25848477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25848477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Some properties of beclomethasone dipropionate and related steroids in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/25848477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of hepatitis B surface antigen in patients with ankylosing spondylitis and its association with HLA-B27: a retrospective study from south China

1 reference

https://pubmed.ncbi.nlm.nih.gov/25848477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4254/WJH.V7.I3.539

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38408897&oldid=2159293608"